// App-Quantinova.ai

495 : Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates

Researchers

Presenter

  • Sergio Schwartzman

Principal Investigators

  • Ronald F van Vollenhoven

  • Alan K Matsumoto

  • Dana Orange

  • Shweta Shah

  • Ryan DeMasi

  • Haiyun Fan

  • Palle Dahl

  • Ann Wouters

  • Edward C. Keystone

Medical Centers

  • Hospital for Special Surgery, New York, NY.

  • Karolinska Institutet, Stockholm, Sweden

  • Arthritis& Rheumatism Assoc PC, Wheaton, MD

  • Rockefeller University; Hospital for Special Surgery; and New York Genome Center, New York, NY

  • Pfizer Inc, Collegeville, PA

  • Pfizer Inc, Ballerup, Denmark

  • Pfizer Inc, New York, NY

  • University of Toronto, Toronto, ON, Canada

Locations

  • United States

  • Sweden

  • Denmark

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Nucleoside diphosphate kinase A

  • C reactive protein

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved